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Abstract
The literature on association between apolipoprotein E (APOE) gene variations and plasma levels of
C-reactive protein (CRP) remains inconsistent, mainly due to low statistical power of previous
studies. To clarify this question, we analysed data from large population sample of randomly
selected individuals from 7 Czech towns (2886 males and 3344 females, the HAPIEE study). In
both males and females, the lowest levels of plasma hsCRP were observed in the carriers of the
APOE ε4ε4 and ε4ε3 genotypes. The median (inter-quartile range, IQR) concentration of hsCRP in
carriers of the most common APOE ε3ε3 genotype (two thirds of participants) was 1.13 (IQR 0.56;
2.33) mg/l in men and 1.23 (IQR 0.61; 2.65) mg/l in women, compared with 0.72 (IQR 0.61; 0.86)
mg/l in male and 0.72 (IQR 0.61-0.85) mg/l in female carriers of APOE ε4ε3/ε4ε4 genotypes; the
differences were statistically significant (p<0.001). The association between APOE and CRP was
not materially affected by adjustment for age, sex, history of cardiovascular disease or
cardiovascular risk factors. This study, the largest to date, provides robust evidence of an
association between plasma hsCRP and the APOE genotype, an association not explained by history
of cardiovascular disease nor its risk factors.
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Introduction
There is an extensive literature on the potential impact of low-grade inflammation in the vascular
endothelium on atherosclerosis development [1]. C-reactive protein (CRP), the acute phase serum
protein produced by liver, has often been used as an overall marker of inflammation . Elevated
plasma levels of CRP have been repeatedly found in patients with cardiovascular disease (CVD)
and myocardial infarction, and it has been proposed that CRP is an independent risk factor of CVD
[2,3], although the pathogenic and clinical significance of CRP remains controversial [4]. In
addition to CVD, plasma levels of CRP have been also found to correlate with CVD risk factors,
such as body mass index, lipid parameters, smoking, and dietary habits [5]. Similarly to other risk
factors of atherosclerosis development, plasma levels of CRP are partially genetically determined
[6-9].
Apolipoprotein E (APOE, gene ID 348, OMIM acc No. 107741) is a multifunctional protein that
playsa key role in the metabolism of plasma lipids and is found on the surface of the triglyceride
rich lipoproteins. Three common APOE alleles (ε2, ε3 and ε4) and many rare mutations have been
described; the frequencies of these variants differ between populations [10-13]. In general,
individuals carrying the ε4 allele [Cys112Arg, rs429358] have higher total cholesterol levels and
persons carrying the ε2 allele [Arg158Cys, rs7412] have lower cholesterol than those carrying the
most common ε3ε3 genotype. The role of the apolipoprotein E, regulated by the APOE gene, in the
inflammatory response has also been suggested [14], and there is some evidence to support such an
effect from studies in both animal models and humans [14,15]. Although data on individual variants
are not entirely consistent, a pro-inflammatory state seems associated with APOE ε4 allele [14]; the
same allele is associated with severe sepsis in surgical patients [16].5
A possible, but physiologically unexplained, association has been suggested between the common
APOE polymorphism and plasma level of CRP. However, the results to date are contradictory.
While initial observations suggested that the highest plasma levels of CRP are in APOE ε3/e3
carriers and the lowest levels in APOE ε4/e4 and APOE ε4/e2 carriers [17], subsequent studies
were not entirely consistent, as shown in table 1 [18-35]. A large part of the apparent
inconsistencies is due to the very low statistical power of most studies (with a few exceptions), the
use of various pre-selected subgroups (e.g. patients with dyslipidaemias or cardiovascular disease,
diabetics or elderly subjects) and unclear methodology. Clarification of the association between
APOE genotype and CRP is important for at least two reasons. First, the biological mechanisms
responsible for the association between APOE genotype and CVD remain unclear; examining
whether associations between APOE and potential cardiovascular risk factors (such as CRP) mirrors
the association of APOE with CVD is therefore helpful in elucidating the causal pathway. Second, it
has long been recognised that apolipoprotein E, and APOE genotype, affect a broad range of
biological functions [36], and there is interest in the effects of APOE on inflammatory response rate
[14].
In this paper, we used data from a large population based study with sufficient statistical power, to
investigate differences in plasma CRP levels by APOE genotype, and whether such differences can
be explained by history of CVD or its risk factors.
Materials and methods
Study subjects
We used data from the Czech part of the HAPIEE (Health, Alcohol and Psychosocial factors In
Eastern Europe) study. Details of the study have been described elsewhere [37]. Briefly, random
population samples of men and women aged 45-69 years from 7 Czech towns (Jihlava, Havirov,6
Hradec Kralove, Karvina, Kromeriz, Liberec and Usti nad Labem) were invited to complete a
questionnaire and to attend an examination in a clinic. A total of 8856 persons completed the
questionnaire (response rate 55%), of whom 7260 attended the examination, 6920 provided blood
sample, and DNA sample was available on 6748 individuals.
Measurements
High-sensitivity (hs-) CRP was measured immunoturbidimetrically by the WHO Lipid Reference
Centre in Prague, using the Roche COBAS MIRA autoanalyzer and reagents from ORION. DNA
was isolated from frozen whole blood using the standard salting-out method [38]. Genotyping of the
APOE gene was performed as described previously [39]. The frequencies of the individual
genotypes are similar to findings in neighbouring populations [11], and deviation from the Hardy-
Weinberg equilibrium was not statistically significant (p values were 0.13 in men, 0.22 in women
and 0.07 in both genders combined). In 7 individuals, a rare APOE mutation Arg136Cys was
detected [40], and these individuals were excluded from the study. In further 73 individuals the
genotyping failed even when repeated three times. A total of 6492 persons had valid data both on
CRP level and APOE genotype.
Statistical analyses
We further excluded subjects who had hsCRP ≥10 mg/L CRP levels (n=262) from the analysis
because of a possible acute infection. The present analyses are thus based on 6230 subjects (2886
males and 3344 females) with full data on CRP and APOE and with hsCRP concentrations <10
mg/L.
Since the distribution of hsCRP levels is highly skewed, to the extent that even logarithmically
transformed values are highly asymmetrically distributed, we used non-parametric methods. First,
we show, for each APOE genotype, and within each sex, the median and inter-quartile range (IQR)7
of hs-CRP concentrations. Second, crude differences in hsCRP levels by APOE genotype were
assessed by the Kruskal-Wallis non-parametric test, separately for men and women. Finally, since
the differences in hsCRP by APOE genotypes were similar in men and women, data from both
genders were pooled, and the relationship between APOE genotype and quartile of hsCRP was
estimated using ordered logistic regression. This approach, while not making assumption about the
distribution of CRP, allows multivariate analysis and therefore adjustment for covariates; we
controlled for age, sex, history of myocardial infarction, angina and stroke (each coded as 0/1),
current smoking, total cholesterol, body mass index (BMI, kg/m
2) and hypertension
(systolic/diastolic blood pressure ≥140/85 mm Hg or antihypertensive medication in the last 2
weeks). The odds ratio derived from ordered logistic regression can be interpreted as the weighted
mean of (i) odds of CRP quartile 1 vs. quartiles 2-4, (ii) odds of quartiles 1-2 vs. quartiles 3-4, and
(iii) odds of quartiles 1-3 vs. quartile 4, associated with a given genotype. The proportional odds
assumption was fulfilled (the p-value from the approximate likelihood-ratio test of proportionality
of odds across CRP quartile response categories was 0.133).
Results
Descriptive characteristics of the subjects included in the analysis are summarized in table 2. The
median CRP levels were slightly higher in men than in women (p<0.001) and, as expected, CRP
was positively correlated with age, BMI and smoking (not shown in table). The distribution of the
APOE genotypes in individuals excluded because of CRP concentration >=10 mg/l did not differ
from the general population (APOE ε2ε2 0.8%, APOE ε2ε3 13.7%, APOE ε3ε3 65.3%, APOE
ε4ε3 16.8%, APOE ε4ε2 2.7%, and APOE ε4ε4 0.8%, not shown in table).
The plasma levels hsCRP by the APOE genotypes are summarized in Table 3. Serum levels of
hsCRP differed highly significantly between APOE genotypes, both by all six individual genotypes8
and by four groups defined by the presence of the APOE alleles, i.e. carriers of the APOE ε2 allele,
APOE ε3ε3 homozygotes and APOE ε4 carriers. The APOE ε2ε4 genotype is also reported
separately, because of the uncertainty about pooling with other genotypes. The differences were of
similar magnitude in males and females. In males, APOE ε3ε3 homozygotes had the highest
median serum hsCRP; similarly, females with APOE ε3ε3 genotype also had high CRP (only very
slightly lower median than APOE ε4ε2 heterozygotes); even in such a large study, however, the
numbers of individuals with specific uncommon genotypes within each sex were insufficient to
provide statistically reliable estimates of hsCRP levels.
Given the similarity of associations in men and women (and the interactions between sex and APOE
were not statistically significant), we pooled the data from both genders, and we used ordered
logistic regression to assess the association between APOE genotype and hsCRP after controlling
for covariates (Table 4). The associations remained strong and highly statistically significant after
adjustment for the age, history of CVD, smoking, BMI, total cholesterol and hypertension. In
addition to lower hsCRP in the combined APOE ε4 group, both APOE ε4ε3 and APOE ε4ε4
genotypes had statistically lower levels of hsCRP than APOE ε3ε3 homozygotes in these pooled
analyses (due to increased statistical power, compared with sex-specific analyses).
Discussion
The present study, the largest on this subject to date, found that the serum hsCRP is independently
determined by the common genetic polymorphisms within the APOE gene. Given the large size
(and hence high statistical power) of this study, these findings provide robust evidence that the
APOE ε4 allele is associated with low levels of plasma hsCRP.9
Previous studies on this subject yielded not results that were not entirely consistent. In some
populations, both ε2 and ε3 carriers were reported to have the highest CRP [17,18]. Some studies of
elderly subjects showed either the highest levels of CRP in APOE ε2 carriers [19,21] or no effect of
APOE genotype on plasma CRP at all [22]. A study in younger adult females found the highest
hsCRP levels in carriers of the APOE ε4 allele [23]. In a recent genome wide association study,
CRP levels had an significant genetic component and APOE was among genes detected to have a
significant effect on plasma CRP; unfortunately, CRP values by the specific alleles were not
available [8].
The discrepancies in previous findings are mainly due to the low statistical power of most previous
studies. In addition, many studies analysed subjects who included patient’s relatives or pre-selected
subgroups, such as dyslipidemic subjects [17,21,27], ethnically non-homogenous populations [20],
the elderly [19,22], or families of patients [24,26]. There were also methodological inconsistencies;
for example, many papers do not specify whether extreme hsCRP levels were excluded from the
analyses (because of the concerns about the presence of acute infection) or the grouping of APOE
genotypes differs between papers. Inappropriate statistics may have also contributed to the
heterogeneous findings: most studies reported geometric means of hsCRP but, given the extremely
skewed distribution of hsCRP, the use of parametric methods is likely to produce misleading
results. Overall, previous data mostly suggest low CRP levels in carriers of ε4, compared to ε3ε3
but the inconsistencies in reporting allow neither reliable conclusions nor formal meta-analysis
without obtaining the raw data.
Our study overcame many of these limitations. First, its size (roughly equivalent to half of all
previous published studies combined) provided sufficient statistical power to study not only groups
of genotypes, but specific genotypes separately. Second, in contrary to many previous
investigations, our study recruited a random general (and ethnically homogenous) population10
sample, rather than patients selected for a particular condition, such as candidates for statin
treatment, diabetics or different ethnicities. Third, our study sample was slightly younger than many
previous studies (the mean age in many studies was considerably higher than sixty years); as age is
an important predictor of CRP, studies in younger subjects are particularly useful. Fourth, we
excluded subjects with high CRP levels, and thus limited misclassification due to possible acute
infection, and used non-parametric methods that do not make assumptions about distribution of
CRP. Finally, our subjects were phenotypically well characterised, enabling us to discount history
of CVD and risk factors for CVD as possible explanations for the relation between APOE genotype
and hsCRP.
The biological basis for the relationship between APOE and hsCRP is not clear. Given that both
plasma apolipoprotein E and CRP come from the same source in organism, the liver, the expression
of these proteins could be regulated by similar factors, but no experimental evidence has been
published so far.
The present results, consistent with the majority of previously published literature, highlight an
important contradiction. On the one hand, individuals with elevated levels of the hsCRP are at
increased risk of mortality and morbidity from multiple disease states including myocardial
infarction, stroke, diabetes, metabolic syndrome [3] and end stage renal disease (ESRD) [14]. On
the other hand, APOE ε4 is associated with increased risk of CVD and ESRD [41]. Yet the CRP
levels are lower in carriers of APOE ε4, which is the “risky” genotype for CVD, and high
concentrations of hsCRP, proposed to be a risk factor of CVD, are not associated with the APOE ε4
allele as would be expected. To complicate the situation further, there is an inverse association
between plasma apolipoprotein E concentration and CRP levels [42], and plasma apolipoprotein
concentrations seem to be higher in APOE ε2 carriers and lower in APOE ε4 carriers [43]. This
suggests that the effects of APOE and CRP operate by different and mutually independent11
mechanisms, or that the APOE genotype is associated with, but is not a causal determinant of
plasma CRP levels.
It is possible that slightly elevated CRP levels, based on genetic predisposition, rather than
inflammatory status, accounts for the elevated risk of vascular disease. Indeed, a large prospective
study has shown that variants in the CRP gene are associated with marked increase of CRP levels
but these polymorphisms were not associated with increased risk of vascular disease [44]. This
would allow for the possibility that adverse effects of increases CRP levels are limited to
inflammation induced environmentally, rather than genetically.
Our study was not designed to investigate the important question of the aetiological role of CRP in
CVD. However, we have clearly demonstrated that the APOE genotype influences CRP
concentrations. Future studies are needed to clarify the implication of this association for the risk of
common diseases, such as vascular diseases.12
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1908.Table 1. Previous population-based studies on APOE genotype and CRP levels.
Note: Studies were identified in PubMed using the following combinations of search terms: (“apoe” or “apo e” or “apoliporotein e”) and
(“genotype” or “gene” or “polymorphisms) and (“crp” or “c-reactive protein”).





Main findings Differences in CRP
statistically
significant?
Kravitz et al. [33] 2009 Persons aged 90+ 3 groups 227 No association No
Angelopoulos et al.
[32]
2008 Healthy volunteers Geometric mean 117 Lower CRP in ε3/ ε4 Marginally
Haan et al. [31] 2008 Elderly Latinos Median 1445 Lower CRP in ε3/ ε4 Yes





2007 General population Geometric mean 1223 Lower CRP in ε4 Yes
Park et al. [34] 2007 Healthy controls Arithmetic mean 119 No association No
Kahri et al. [26] 2006 Low HDL & normo-
lipidaemic subjects.
Geometric mean 368 CRP lower in ε4 Yes
Tziakas et al. [29] 2006 Patients with angina & acute
coronary syndrome
Non-parametric 166 CRP lower in ε4 Yes
Ravaglia et al. [30] 2006 General 65+ Binary 671 CRP lower in ε4 No
Lange et al. [20] 2006 Diabetics Geometric mean 241 CRP lower in ε4 Marginally
Mooijaart et al. [22] 2006 Persons aged 85+ Geometric mean 594 CRP lower in ε4 Yes
Chasman et al. [25] 2006 General population Geometric mean 2053 CRP lower in ε4 Yes
Rontu et al. [19] 2006 90+ Geometric mean 291 CRP lower in ε4 Yes
Eiriksdotrir et al. [21] 2006 Older general population Geometric mean 2251 CRP lower in ε4 Yes
Paschos et al. [28] 2005 Dyslipidaemic Median 50 CRP lower in ε4 No
Judson et al. [27] 2004 Dislipidaemic Geometric mean 600 CRP lower in ε4 yes
Marz et al. [18] 2004 Patients with CHD and
healthy controls
Geometric mean 1309 CRP lower in ε4 Yes
Austin et al. [35] 2004 Japanese Americans from
68 kindreds
Geometric mean 558 CRP similar in ε4 and
ε3/ ε3 but lower than
in ε2
Marginally
Manttari et al. [17] 2001 Cases of MI and controls Arithmetic mean 177 CRP lower in ε4 YesTable 2
Basic characteristics of subjects included in the analysis.
Men Women
N 2886 3344
Age, mean (SD), years 58.2 (7.2) 57.4 (7.2)
Total cholesterol, mean (SD), mmol/l 5.62 (1.04) 5.82 (1.04)
BMI, mean (SD), kg/m
2 28.2 (3.9) 27.9 (4.9)
Hypertension, % 72.5% 57.9%
Current smoking prevalence, % 25.9% 20.3%
History of myocardial infarction, % 7.8% 2.4%
History of angina, % 5.1% 3.3%
History of stroke, % 3.5% 2.5%
CRP, median (IQR), mg/l 1.08 (0.56, 2.19) 1.19 (0.57, 2.61)21
Table 3
Median (IQR) concentrations of CRP by APOE genotype and odds ratios (95% confidence
intervals) from ordered logistic regression (with quartiles of CRP as dependent variable), by sex.
APOE N % Median (IQR) of CRP
concentrations (mg/l).
Odds ratio (95% CI)
Men











































































































* Kruskal-Wallis non-parametric test.22
Table 4
Crude and adjusted odds ratios (95% confidence intervals) by APOE genotype from ordered logistic
regression, with quartiles of CRP concentrations as dependent variable; pooled data from men and
women.
APOE genotype N % Crude OR (95% CI) Adjusted OR (95% CI)*



















































* adjusted for adjusted for age, sex, total cholesterol, hypertension, body mass index, smoking, and
history of angina, myocardial infarction and stroke.